• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Intertek banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Nasus Pharma says its FMXIN002 intranasal dry powder epinephrine demonstrated 5 years stability

According to Nasus Pharma, a stability study of the company’s FMXIN002 nasal epinephrine powder demonstrated full stability for the formulation and device over 5 years of storage at 15 to 25℃. The company said that at 5 years, the epinephrine level was at 97.5%, with degradation products at 0.37%. Nasus noted that a previous stability test at 40℃ and 75% humidity demonstrated full stability at 6 months.

Nasus is developing FMXIN002 for the treatment of anaphylaxis and has previously reported positive PK data for the nasal powder compared to EpiPen. The company points out that solution formulations of epinephrine require the use of stabilizers and have expiration dates that range from 12 to 18 months.

Nasus CEO Dalia Megiddo commented, “The results of our long-term stability study as well as the results from our Phase 2 clinical study are further confirmation of the advantages of our proprietary powder intranasal epinephrine FMXIN002 in offering [an] easy-to-use, reliable small device that can be carried around in a small pocket and is a highly effective immediate treatment  for anaphylactic shock.”

Executive Chairman of the Board Udi Gilboa said, “We are extremely encouraged by the data generated by the company up until today including the latest outstanding results showing unheard of epinephrine stability of 5 years. The commercial potential of our powder-based epinephrine product and its potential to become the fastest-acting, simple-to-administer, needle-free nasal spray, provides patients and caregivers with the most promising alternative for this growing Type 1 allergic reaction market. . . . Yet an additional advantage for powder-based formulation of epinephrine, a drug that undergoes rapid degradation in the currently available short shelf-life liquid dosage forms.”

Read the Nasus Pharma press release.

Share

published on August 7, 2024

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Merxin We Make Inhalers banner
    © 2025 OINDPnews